Exagen (XGN) Projected to Post Earnings on Tuesday

Exagen (NASDAQ:XGN - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, July 29th. Analysts expect Exagen to post earnings of ($0.18) per share and revenue of $16.25 million for the quarter.

Exagen (NASDAQ:XGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). Exagen had a negative net margin of 27.34% and a negative return on equity of 133.69%. The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. During the same quarter in the prior year, the firm posted ($0.19) EPS. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Price Performance

Shares of NASDAQ:XGN traded down $0.03 during trading on Tuesday, reaching $6.94. 235,081 shares of the stock were exchanged, compared to its average volume of 147,210. Exagen has a 1-year low of $1.78 and a 1-year high of $7.95. The company has a debt-to-equity ratio of 2.87, a current ratio of 2.32 and a quick ratio of 2.32. The stock has a fifty day moving average of $6.84 and a two-hundred day moving average of $5.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. BTIG Research reissued a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Cantor Fitzgerald decreased their target price on Exagen from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. UBS Group reissued an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Finally, Canaccord Genuity Group raised their price objective on Exagen from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Tuesday, May 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $7.50.

Institutional Investors Weigh In On Exagen

A hedge fund recently bought a new stake in Exagen stock. Acadian Asset Management LLC purchased a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,984 shares of the company's stock, valued at approximately $25,000. Hedge funds and other institutional investors own 75.25% of the company's stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).